molecular markers beyond kras for anti-egfr targeted agents — what is new?
Published 10 years ago • 985 plays • Length 24:33Download video MP4
Download video MP3
Similar videos
-
17:17
debate: targeted therapy for ras/braf wt left sided colon cancers - egfr antibodies are mandatory
-
22:04
which biological targeted agent and for whom?
-
22:46
mutational testing and the treatment of colorectal cancer
-
24:01
update 2: molecular targets & novel agents for gastric cancer
-
11:54
debate: targeted therapy for ras/braf wt left sided colon cancers - bevacizumab or egfr antibodies
-
22:37
new drugs and targets in colorectal cancer gastrointestinal cancer
-
32:17
part 2: clinical utility of angiogenesis inhibitors in metastatic colorectal cancer
-
47:45
resistance in braf and kras mutant cancers - by ryan corcoran, md, phd
-
23:09
colorectal cancer: updates on novel agents and targets
-
21:31
is kras "actionable" in the management of nsclc
-
35:02
gracecast-039_lung-cancer_pennell nsclc molecular markers webinar
-
41:03
part 1: clinical utility of angiogenesis inhibitors in metastatic colorectal cancer
-
14:38
beyond egfr and vegfr inhibitors: targeting the ras/raf/mek and alternative pathway in crc
-
21:35
long term management of egfr-mutant nsclc -tsao
-
23:42
current status of adjuvant therapy for nsclc
-
27:43
targeting the immune system with checkpoint inhibitors
-
23:10
egfr mutation positive tumors: treatment strategies in front line and at relapse
-
20:05
impact of molecular subsets in colorectal cancer on adjuvant and advanced disease therapy
-
28:17
segment 1: egfr tkis in nsclc